PREFER: patient preferences
@IMI_PREFER
Followers
762
Following
608
Statuses
1K
PREFER looks at why, when and how to assess and use patient preferences in medical product decision-making.
Joined February 2018
RT @PFMDwithPatient: Rebecca Noel, Global Leader for Benefit-Risk Assessment @EliLillyandCo & member of @IMI_PREFER speaks to the value of…
0
1
0
Comparing Outcomes of a Discrete Choice Experiment and Case 2 Best-Worst Scaling: An Application to Neuromuscular Disease Treatment 👇
0
2
3
RT @AMR_Combine: People affected with bacterial infections can & should be involved in every step of antibiotic #DrugDevelopment🗨️ Read thr…
0
6
0
We have shared our reports and templates #OpenAccess. Want to use them? Take a look at the PREFER Zenodo community!
Today is our 10th anniversary 🎉 Use #Zenodo10Years to celebrate with us by sharing YOUR story on how Zenodo helped YOU! #OpenScience @CERN @OpenAIRE_eu
0
1
3
Want to know why, when and how PREFER recommends that pharma, regulators, HTA bodies and payers assess and use patient preferences in medical product decision-making?
0
6
5
We received a positive qualification opinion on the PREFER framework and points to consider for method selection for a patient preference study from @EMA_News. Want to know more about the process? 👇
0
0
0
Why, when and how to assess and use patient preferences in medical product decision-making. The PREFER Recommendations
0
1
1
RT @IHIEurope: Missed our #ImpactSeriesIMI event yesterday on early career researchers? Catch up online: @van_over…
0
3
0
RT @IHIEurope: 17 papers published, 12 presentations at congresses and multiple interactions with diverse stakeholders... @van_overbeeke s…
0
4
0
RT @IHIEurope: Our #ImpactSeriesIMI speakers outline the benefits for early career researchers of joining a PPP project ... - Good overvie…
0
4
0
Take-home messages from the PREFER Recommendations, explaining when and why structured input from patient preference studies can support decision making. 👇
0
0
0
RT @IHIEurope: .@van_overbeeke played a key role in the @IMI_PREFER project's PAVING study which explored what matters to Belgian haemophil…
0
3
0
RT @IHIEurope: Our webinar on IMI's impact on early career researchers is on Monday! This will be a great event featuring some inspiring y…
0
2
0
RT @DrMarieFalahee: Involving patient research partners in preference studies requires dedicated resources and expertise, but it's worth it…
0
5
0
JUST PUBLISHED: Patients as research partners in preference studies: learnings from IMI-PREFER 👇
0
1
6
Preferences for preventive treatments for #rheumatoidarthritis: discrete choice survey in the UK, Germany and Romania 👇
0
1
3
Acceptable risks of treatments to prevent #rheumatoidarthritis among first-degree relatives: demographic and psychological predictors of risk tolerance 👇
0
0
0
RT @IHIEurope: ⏰Our #ImpactSeriesIMI event on IMI's impact on early career researchers is in 2 weeks! Meet @van_overbeeke of @IMI_PREFER @I…
0
8
0
RT @IHIEurope: How do public-private partnerships help early career researchers (ECRs) get ahead professionally? Find out from ECRs from I…
0
8
0
Examining patient and professional perspectives in the UK for gene therapy in #haemophilia #PREFERlegacy 👇
0
1
1